Propensity score-matched analysis of long-term outcomes for living kidney donation in alternative complement pathway diseases: a pilot study.
Atypical hemolytic uremic syndrome
C3 glomerulopathy
Complement
Kidney
Living donation
Transplantation
Journal
Journal of nephrology
ISSN: 1724-6059
Titre abrégé: J Nephrol
Pays: Italy
ID NLM: 9012268
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
received:
07
09
2022
accepted:
15
01
2023
medline:
31
5
2023
pubmed:
23
2
2023
entrez:
22
2
2023
Statut:
ppublish
Résumé
Atypical hemolytic syndrome (aHUS) and C3 glomerulopathy (C3G) are complement-mediated rare diseases with excessive activation of the alternative pathway. Data to guide the evaluation of living-donor candidates for aHUS and C3G are very limited. The outcomes of living donors to recipients with aHUS and C3G (Complement disease-living donor group) were compared with a control group to improve our understanding of the clinical course and outcomes of living donation in this context. Complement disease-living donor group [n = 28; aHUS(53.6%), C3G(46.4%)] and propensity score-matched control-living donor group (n = 28) were retrospectively identified from 4 centers (2003-2021) and followed for major cardiac events (MACE), de novo hypertension, thrombotic microangiopathy (TMA), cancer, death, estimated glomerular filtration rate (eGFR) and proteinuria after donation. None of the donors for recipients with complement-related kidney diseases experienced MACE or TMA whereas two donors in the control group developed MACE (7.1%) after 8 (IQR, 2.6-12.8) years (p = 0.15). New-onset hypertension was similar between complement disease and control donor groups (21.4% vs 25%, respectively, p = 0.75). There were no differences between study groups regarding last eGFR and proteinuria levels (p = 0.11 and p = 0.70, respectively). One related donor for a recipient with complement-related kidney disease developed gastric cancer and another related donor developed a brain tumor and died in the 4th year after donation (2, 7.1% vs none, p = 0.15). No recipient had donor-specific human leukocyte antigen antibodies at the time of transplantation. Median follow-up period of transplant recipients was 5 years (IQR, 3-7). Eleven (39.3%) recipients [aHUS (n = 3) and C3G (n = 8)] lost their allografts during the follow-up period. Causes of allograft loss were chronic antibody-mediated rejection in 6 recipients and recurrence of C3G in 5. Last serum creatinine and last eGFR of the remaining patients on follow up were 1.03 ± 038 mg/dL and 73.2 ± 19.9 m/min/1.73 m2 for aHUS patients and 1.30 ± 0.23 mg/dL and 56.4 ± 5.5 m/min/1.73 m2 for C3G patients. The present study highlights the importance and complexity of living related-donor kidney transplant for patients with complement-related kidney disorders and motivates the need for further research to determine the optimal risk-assessment for living donor candidates to recipients with aHUS and C3G.
Sections du résumé
BACKGROUND
Atypical hemolytic syndrome (aHUS) and C3 glomerulopathy (C3G) are complement-mediated rare diseases with excessive activation of the alternative pathway. Data to guide the evaluation of living-donor candidates for aHUS and C3G are very limited. The outcomes of living donors to recipients with aHUS and C3G (Complement disease-living donor group) were compared with a control group to improve our understanding of the clinical course and outcomes of living donation in this context.
METHODS
Complement disease-living donor group [n = 28; aHUS(53.6%), C3G(46.4%)] and propensity score-matched control-living donor group (n = 28) were retrospectively identified from 4 centers (2003-2021) and followed for major cardiac events (MACE), de novo hypertension, thrombotic microangiopathy (TMA), cancer, death, estimated glomerular filtration rate (eGFR) and proteinuria after donation.
RESULTS
None of the donors for recipients with complement-related kidney diseases experienced MACE or TMA whereas two donors in the control group developed MACE (7.1%) after 8 (IQR, 2.6-12.8) years (p = 0.15). New-onset hypertension was similar between complement disease and control donor groups (21.4% vs 25%, respectively, p = 0.75). There were no differences between study groups regarding last eGFR and proteinuria levels (p = 0.11 and p = 0.70, respectively). One related donor for a recipient with complement-related kidney disease developed gastric cancer and another related donor developed a brain tumor and died in the 4th year after donation (2, 7.1% vs none, p = 0.15). No recipient had donor-specific human leukocyte antigen antibodies at the time of transplantation. Median follow-up period of transplant recipients was 5 years (IQR, 3-7). Eleven (39.3%) recipients [aHUS (n = 3) and C3G (n = 8)] lost their allografts during the follow-up period. Causes of allograft loss were chronic antibody-mediated rejection in 6 recipients and recurrence of C3G in 5. Last serum creatinine and last eGFR of the remaining patients on follow up were 1.03 ± 038 mg/dL and 73.2 ± 19.9 m/min/1.73 m2 for aHUS patients and 1.30 ± 0.23 mg/dL and 56.4 ± 5.5 m/min/1.73 m2 for C3G patients.
CONCLUSION
The present study highlights the importance and complexity of living related-donor kidney transplant for patients with complement-related kidney disorders and motivates the need for further research to determine the optimal risk-assessment for living donor candidates to recipients with aHUS and C3G.
Identifiants
pubmed: 36808609
doi: 10.1007/s40620-023-01588-x
pii: 10.1007/s40620-023-01588-x
doi:
Substances chimiques
Complement System Proteins
9007-36-7
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
979-986Subventions
Organisme : Ulusal Metroloji Enstitüsü, Türkiye Bilimsel ve Teknolojik Araştirma Kurumu
ID : 114S261
Informations de copyright
© 2023. The Author(s) under exclusive licence to Italian Society of Nephrology.
Références
Noris M, Remuzzi G (2015) Glomerular diseases dependent on complement activation, including atypical hemolytic uremic syndrome, membranoproliferative glomerulonephritis, and C3 glomerulopathy: core curriculum 2015. Am J Kidney Dis 66(2):359–375
doi: 10.1053/j.ajkd.2015.03.040
pubmed: 26032627
pmcid: 4528072
Caliskan Y, Torun ES, Tiryaki TO, Oruc A, Ozluk Y, Akgul SU et al (2017) Immunosuppressive treatment in C3 glomerulopathy: is it really effective? Am J Nephrol 46(2):96–107
doi: 10.1159/000479012
pubmed: 28700996
Halimi JM, Al-Dakkak I, Anokhina K, Ardissino G, Licht C, Lim WH et al (2022) Clinical characteristics and outcomes of a patient population with atypical hemolytic uremic syndrome and malignant hypertension: analysis from the Global aHUS registry. J Nephrol. https://doi.org/10.1007/s40620-022-01465-z
doi: 10.1007/s40620-022-01465-z
pubmed: 36152218
pmcid: 10090001
Wolfe RA, Ashby VB, Milford EL, Ojo AO, Ettenger RE, Agodoa LY et al (1999) Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 341(23):1725–1730
doi: 10.1056/NEJM199912023412303
pubmed: 10580071
Jokiranta TS, Zipfel PF, Fremeaux-Bacchi V, Taylor CM, Goodship TJ, Noris M (2007) Where next with atypical hemolytic uremic syndrome? Mol Immunol 44(16):3889–3900
doi: 10.1016/j.molimm.2007.06.003
pubmed: 17768107
Knoop M, Haller H, Menne J (2018) Human genetics in atypical hemolytic uremic syndrome-its role in diagnosis and treatment. Internist (Berl) 59(8):799–804
doi: 10.1007/s00108-018-0455-9
pubmed: 29995248
Oto OA, Safak S, Mirioglu S, Yelken B, Velioglu A, Dirim AB et al (2022) Long-term outcomes of living-related kidney donation for alport syndrome spectrum: a propensity score-matched analysis. Am J Nephrol 53:1–8
doi: 10.1159/000527180
Donne RL, Abbs I, Barany P, Elinder CG, Little M, Conlon P et al (2002) Recurrence of hemolytic uremic syndrome after live related renal transplantation associated with subsequent de novo disease in the donor. Am J Kidney Dis 40(6):E22
doi: 10.1053/ajkd.2002.36938
pubmed: 12460067
Zuber J, Frimat M, Caillard S, Kamar N, Gatault P, Petitprez F et al (2019) Use of highly individualized complement blockade has revolutionized clinical outcomes after kidney transplantation and renal epidemiology of atypical hemolytic uremic syndrome. J Am Soc Nephrol 30(12):2449–2463
doi: 10.1681/ASN.2019040331
pubmed: 31575699
pmcid: 6900783
Pickering MC, D’Agati VD, Nester CM, Smith RJ, Haas M, Appel GB et al (2013) C3 glomerulopathy: consensus report. Kidney Int 84(6):1079–1089
doi: 10.1038/ki.2013.377
pubmed: 24172683
pmcid: 3842953
Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J et al (2015) Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17(5):405–424
doi: 10.1038/gim.2015.30
pubmed: 25741868
pmcid: 4544753
Choi BG, Rha SW, Yoon SG, Choi CU, Lee MW, Kim SW (2019) Association of major adverse cardiac events up to 5 years in patients with chest pain without significant coronary artery disease in the Korean Population. J Am Heart Assoc 8(12):e010541
doi: 10.1161/JAHA.118.010541
pubmed: 31185781
pmcid: 6645628
Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI et al (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150(9):604–612
doi: 10.7326/0003-4819-150-9-200905050-00006
pubmed: 19414839
pmcid: 2763564
Noris M, Remuzzi G (2009) Atypical hemolytic-uremic syndrome. N Engl J Med 361(17):1676–1687
doi: 10.1056/NEJMra0902814
pubmed: 19846853
Kant S, Bhalla A, Alasfar S, Alachkar N (2020) Ten-year outcome of Eculizumab in kidney transplant recipients with atypical hemolytic uremic syndrome—a single center experience. BMC Nephrol 21(1):189
doi: 10.1186/s12882-020-01847-0
pubmed: 32434487
pmcid: 7238522
Salvadori M, Bertoni E (2013) Update on hemolytic uremic syndrome: diagnostic and therapeutic recommendations. World J Nephrol 2(3):56–76
doi: 10.5527/wjn.v2.i3.56
pubmed: 24255888
pmcid: 3832913
Ardissino G, Longhi S, Porcaro L, Pintarelli G, Strumbo B, Capone V et al (2021) Risk of atypical HUS among family members of patients carrying complement regulatory gene abnormality. Kidney Int Rep 6(6):1614–1621
doi: 10.1016/j.ekir.2021.03.885
pubmed: 34169201
pmcid: 8207326
Esparza-Gordillo J, Goicoechea de Jorge E, Buil A, Carreras Berges L, Lopez-Trascasa M, Sanchez-Corral P, et al (2005) Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32. Hum Mol Genet 14(5):703–12
Caliskan Y, Lee B, Whelan A, Abualrub F, Lentine KL, Jittirat A (2022) Evaluation of genetic kidney diseases in living donor kidney transplantation: towards precision genomic medicine in donor risk assessment. Curr Transplant Rep 9(2):127–142
doi: 10.1007/s40472-021-00340-3
pubmed: 35765363
pmcid: 9236183
Raina R, Krishnappa V, Blaha T, Kann T, Hein W, Burke L et al (2019) Atypical hemolytic-uremic syndrome: an update on pathophysiology, diagnosis, and treatment. Ther Apher Dial 23(1):4–21
doi: 10.1111/1744-9987.12763
pubmed: 30294946
Avasare RS, Canetta PA, Bomback AS, Marasa M, Caliskan Y, Ozluk Y et al (2018) Mycophenolate Mofetil in combination with steroids for treatment of C3 glomerulopathy: a case series. Clin J Am Soc Nephrol 13(3):406–413
doi: 10.2215/CJN.09080817
pubmed: 29326307
pmcid: 5967675
Caliskan Y, Lentine KL (2022) Approach to genetic testing to optimize the safety of living donor transplantation in Alport syndrome spectrum. Pediatr Nephrol 37(9):1981–1994
doi: 10.1007/s00467-022-05430-7
pubmed: 35088158
Ducloux D, Rebibou JM, Semhoun-Ducloux S, Jamali M, Fournier V, Bresson-Vautrin C et al (1998) Recurrence of hemolytic-uremic syndrome in renal transplant recipients: a meta-analysis. Transplantation 65(10):1405–1407
doi: 10.1097/00007890-199805270-00023
pubmed: 9625029
Bergstein J, Michael A Jr, Kellstrand C, Simmons R, Najarian J (1974) Hemolytic-uremic syndrome in adult sisters. Transplantation 17(5):487–490
doi: 10.1097/00007890-197405000-00007
pubmed: 4597177
Kaplan BS, Papadimitriou M, Brezin JH, Tomlanovich SJ, Zulkharnain (1997) Renal transplantation in adults with autosomal recessive inheritance of hemolytic uremic syndrome. Am J Kidney Dis 30(6):760-765
Revel M, Daugan MV, Sautes-Fridman C, Fridman WH, Roumenina LT (2020) Complement system: promoter or suppressor of cancer progression? Antibodies (Basel) 9(4):57
doi: 10.3390/antib9040057
pubmed: 33113844